Sage Therapeutics, Inc. (SAGE): Price and Financial Metrics

Sage Therapeutics, Inc. (SAGE)

Today's Latest Price: $42.92 USD

1.19 (-2.70%)

Updated Jul 10 4:00pm

Add SAGE to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 338 in Biotech

See all "A" rated Strong Buy stocks

SAGE Stock Summary

  • SAGE's price/sales ratio is 256.45; that's higher than the P/S ratio of 98.43% of US stocks.
  • Revenue growth over the past 12 months for Sage Therapeutics Inc comes in at -90.42%, a number that bests only 1.14% of the US stocks we're tracking.
  • In terms of volatility of its share price, SAGE is more volatile than 96.27% of stocks we're observing.
  • If you're looking for stocks that are quantitatively similar to Sage Therapeutics Inc, a group of peers worth examining would be GBT, RESN, FGEN, NVTA, and CUE.
  • SAGE's SEC filings can be seen here. And to visit Sage Therapeutics Inc's official web site, go to
SAGE Daily Price Range
SAGE 52-Week Price Range

SAGE Stock Price Chart Technical Analysis Charts

SAGE Price/Volume Stats

Current price $42.92 52-week high $193.56
Prev. close $44.11 52-week low $25.01
Day low $42.88 Volume 545,812
Day high $44.71 Avg. volume 1,061,007
50-day MA $38.95 Dividend yield N/A
200-day MA $73.15 Market Cap 2.23B

Sage Therapeutics, Inc. (SAGE) Company Bio

Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing and commercializing novel medicines to treat life-threatening, rare central nervous system, or CNS, disorders. The company was founded in 2010 and is based in Cambridge, Massachusetts.

SAGE Latest News Stream

Event/TimeNews Detail
Loading, please wait...

SAGE Latest Social Stream

Loading social stream, please wait...

View Full SAGE Social Stream

Latest SAGE News From Around the Web

Below are the latest news stories about Sage Therapeutics Inc that investors may wish to consider to help them evaluate SAGE as an investment opportunity.

Edited Transcript of SAGE earnings conference call or presentation 7-May-20 8:30pm GMT

Q1 2020 SAGE Therapeutics Inc Earnings Call

Yahoo | June 24, 2020

Neurocrine Adds to Pipeline With $2 Billion Takeda Deal

Biotech gets 7 drugs in partnership, 3 of which are in phase 2 testing Continue reading...

Yahoo | June 17, 2020

Sage Therapeutics (SAGE) Presents At Goldman Sachs Global Healthcare Conference - Slideshow

The following slide deck was published by Sage Therapeutics, Inc. in conjunction with this event....

SA Transcripts | June 12, 2020

Is There Any Hope Left for Sage Therapeutics?

The company, which failed pivotal clinical trials investigating major depression, aims to reverse its fortunes this year.

Yahoo | June 9, 2020

Sage Therapeutics to Present at Goldman Sachs 41st Annual Global Healthcare Conference

Sage Therapeutics, Inc. (NASDAQ:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will present at the Goldman Sachs 41st Annual Global Healthcare Conference on Wednesday, June 10, 2020 at 3:00 p.m. ET.

Yahoo | June 1, 2020

Read More 'SAGE' Stories Here

SAGE Price Returns

1-mo 18.53%
3-mo 50.86%
6-mo -44.03%
1-year -77.41%
3-year -46.93%
5-year -43.17%
YTD -40.55%
2019 -24.64%
2018 -41.84%
2017 222.58%
2016 -12.42%
2015 59.29%

Continue Researching SAGE

Here are a few links from around the web to help you further your research on Sage Therapeutics Inc's stock as an investment opportunity:

Sage Therapeutics Inc (SAGE) Stock Price | Nasdaq
Sage Therapeutics Inc (SAGE) Stock Quote, History and News - Yahoo Finance
Sage Therapeutics Inc (SAGE) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8328 seconds.